The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment
Open accessAbstract
The medical and surgical treatment strategies for women with epithelial ovarian cancer continue to evolve. In the past several years, there has been significant progress backed by landmark clinical trials. Although primary epithelial ovarian cancer is still treated with a combination of surgery and systemic therapy, more complex surgical procedures and novel therapeutics have emerged as standard of care. Cytotoxic chemotherapy and maximal surgical effort remain mainstays, but targeted therapies are becoming more widespread and new data have called into question the role of surgery for women with recurrent disease. Poly ADP-ribose polymerase inhibitors have improved progression-free survival outcomes in both the frontline and recurrent settings, and their use has become increasingly widespread. The recent creation of treatment categories based on genetic changes reinforces the recommendation that all women with epithelial ovarian cancer have germline genetic testing, and new biomarker-driven drug approvals indicate that women may benefit from somatic molecular testing as well. To continue to identify novel strategies, however, enrollment on clinical trials remains of the utmost importance. With the evolving data on surgical approaches, targeted therapies such as antiangiogenics and poly ADP-ribose polymerase inhibitors, and the new therapeutic agents and combinations in development, we hope that advanced epithelial ovarian cancer will eventually transition from an almost universally fatal disease to one that can increasingly be cured.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Ovarian cancer statistics, 2018
Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., Gaudet, M. M., Jemal, A., & Siegel, R. L. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21456 · Cited by 3,492
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I., Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,537
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Self-citationNiraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
González-Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., McCormick, C., Lorusso, D., Hoskins, P., Freyer, G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910962 · Cited by 2,263
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., Fujiwara, K., Vergote, I., Colombo, N., Mäenpää, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911361 · Cited by 2,055
Research works printed but not linked: 7
- Onda, 2020, Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial, Eur J Cancer, 130, 114, 10.1016/j.ejca.2020.02.020 · doi:10.1016/j.ejca.2020.02.020
- Kurnit, 2019, Effects of gastrointestinal-type chemotherapy in women with ovarian mucinous carcinoma, Obstet Gynecol, 134, 1253, 10.1097/AOG.0000000000003579 · doi:10.1097/aog.0000000000003579
- Spriggs, 2018, Ovarian cancer treatment—are we getting warmer?, N Engl J Med, 378, 293, 10.1056/NEJMe1714556 · doi:10.1056/nejme1714556
- Koole, 2020, Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial, Int J Gynecol Cancer, 30, 888, 10.1136/ijgc-2020-001231 · doi:10.1136/ijgc-2020-001231
- van der Noll, 2019, Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2), Invest New Drugs, 38, 1096, 10.1007/s10637-019-00857-6 · doi:10.1007/s10637-019-00857-6
- 2018, Cascade testing: testing women for known hereditary genetic mutations associated with cancer. ACOG Committee Opinion No. 727. American College of Obstetricians and Gynecologists, Obstet Gynecol, 131, e31, 10.1097/AOG.0000000000002457 · doi:10.1097/aog.0000000000002457
- Javellana, 2019, The road to long-term survival: surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer, Gynecol Oncol, 152, 228, 10.1016/j.ygyno.2018.11.007 · doi:10.1016/j.ygyno.2018.11.007
Cited by
Deep Visual Proteomics defines single-cell identity and heterogeneity
Mund, A., Coscia, F., Kriston, A., Hollandi, R., Kovács, F., Brunner, A.-D., Migh, E., Schweizer, L., Santos, A., Bzorek, M., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01302-5 · Cited by 562
Self-citationLengyel, E., Li, Y., Weigert, M., Zhu, L., Eckart, H., Javellana, M., Ackroyd, S., Xiao, J., Olalekan, S., Glass, D., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111838 · Cited by 78
“3 There are more than 30 histological subtypes of benign, borderline, and malignant ovarian tumors listed in the World Health Organization (WHO) clinical staging system, and many of these have no identified cell of origin.”
Self-citationSensitization of cancer cells to paclitaxel-induced apoptosis by canagliflozin
Huang, H., Kung, F.-L., Huang, Y.-W., Hsu, C.-C., Guh, J.-H., & Hsu, L.-C. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116140 · Cited by 12
Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
Cvrljevic, A. N., Butt, U., Huhtinen, K., Grönroos, T. J., Böckelman, C., Lassus, H., Butzow, R., Haglund, C., Kaipio, K., Arsiola, T., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0622 · Cited by 5
Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype
Cvrljevic, A. N., Butt, U., Huhtinen, K., Grönroos, T. J., Böckelman, C., Lassus, H., Kaipio, K., Arsiola, T., Laajala, T. D., Connolly, D. C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.31.437804 · Cited by 5
Metadata
- Authors
- Kurnit, K. C., Fleming, G. F., & Lengyel, E.
- Venue
- Obstetrics & Gynecology
- Published
- 2020-12-01
- Volume
- 137
- Issue
- 1
- Pages
- 108-121
- ISSN
- 0029-7844 (ISSN-L)
- OpenAlex
- W3109819734
- Cited by
- 322
- References
- 78
- FWCI
- 28.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. https://app.cochat.ai/papers/10.1097/aog.0000000000004173
- The paper
- Kurnit, K. C., Fleming, G. F., & Lengyel, E. (2021). Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. Obstetrics & Gynecology. https://doi.org/10.1097/aog.0000000000004173
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
